Home Sectors Healthcare Present Fundamentals: CryoLife (NYSE: CRY)

Present Fundamentals: CryoLife (NYSE: CRY)

SHARE

CryoLife is part of the medical devices industry and healthcare sector. The company CEO is James Patrick Mackin. Cryolife Inc is engaged in medical device manufacturing and distribution and in the processing and distribution of implantable human tissues for use in cardiac and vascular surgeries. It has two segments: Medical Devices and Preservation Services.

Previous Intraday Trading Performance:

The CRY stock showed a previous change of 0.21% with an open at 29.37 and a close of 29.34. It reached an intraday high of 29.75 and a low of 29.18.

PR Newswire:  CryoLife to Present at Cowen and Company 39th Annual Health Care Conference

Liquidity:

The stock has a market cap of $1.1b with 37.0m shares outstanding, of which the float is 33.3m shares. Trading volume reached 130,809 shares compared to its average volume of 210,402 shares. Based on the current average volume and close price, the trading liquidity is bad, highly speculative and an investor may want to avoid this stock.

Historical Trading Performance:

Over the last five trading days, CryoLife shares returned 1.66% and in the past 30 trading days it returned 7.83%. Over three months, it changed 1.88%. In one year it has changed 36.15% and within that year its 52-week high was 36.05 and its 52-week low was 19.05. CRY stock is 54.02% above its 52 Week Low.

Our calculations show a 200 day moving average of 30.07 and a 50 day moving average of 28.43. Currently CRY stock is trading -2.41% below its 200 day moving average and may be a good opportunity to buy, but should check other indicators to confirm a buy signal.

PR Newswire:  CryoLife to Present at Cowen and Company 39th Annual Health Care Conference

Earnings:

The last annual fiscal EPS for the company was reported at 0.25 that ended on 31st of December 2018. Based on 1 analyst estimate, the estimated EPS for the next quarter is 0.12. The TTM EPS is 0.25, which comes to a TTM PE of 117.36.

The following are the last four quarter reported earnings per share:
12-31-2018:  0.05
09-30-2018:  0.08
06-30-2018:  0.10
03-31-2018:  0.02

Base on our calculations, the intrinsic value per share is 10.97, which means it may be overvalued by -167.46%

Indicators to Watch:

Based on the latest filings, there is 119.30% of institutional ownership. Short-interest is 656,545, which is 1.77% of shares outstanding. The short-interest ratio or days-to-cover ratio is 3.02. This stock has some short interest, but it may be normal and no cause for concern if long the position.

The current calculated beta is 0.54

SeekingAlpha:  Corindus Vascular Robotics, Inc. (CVRS) CEO Mark Toland on Q4 2018 Results – Earnings Call Transcript

Fundamental Indicators:

Based on last reported financials, the company’s return on equity is -1.04%, return on assets is -0.50%, profit margin is -1.02%, price-to-sales is 4.12 and price-to-book is 3.94.

Company Scores:

All scores are out of six:
 1  :Valuation Score
 0  :Past Performance Score
 1  :Financial Strength Score
 4  :Future Growth Score
 0  :Dividend Score
 1  :Overall Score

SHARE
John Jones
Worked for several Wall Street firms: Salomon Smith Barney, UBS, and Charles Schwab. Has developed skills and gained extensive experience over the years that is used today to uncover winning penny stocks.Also was an attorney for small businesses in Scottsdale, Arizona. That experience and understanding of law provides a unique perspective and edge in discovering quality companies in various industries.